$ALMS:NASDAQ · ALUMIS INC.
Conviction from: NASDAQ
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders.
More about this company
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Not currently held by tracked 13F filers — this page aggregates activist, insider, politician and research activity.
Beyond 13F — activists, insiders, politicians & research
| Filed | Form | Activist | % of class | Conviction | |
|---|
| 2026-04-03 | SCHEDULE 13D/A | Foresite Capital Fund VI LP | 12.7% | Med | filing |
| 2026-01-13 | SCHEDULE 13D/A | Samsara BioCapital, L.P. | 5.4% | Med | filing |
| 2026-01-12 | SCHEDULE 13D/A | Foresite Capital Fund VI LP | 14.1% | Med | filing |
| Filed | Insider | Role | Shares | Value | |
|---|
| 2026-01-13 | AKKARAJU SRINIVAS (cluster of 4) | director | 588,235 | $9,999,995 | Form 4 |
| 2026-01-12 | Tananbaum James B. (cluster of 4) | director+10%-owner | 411,764 | $6,999,988 | Form 4 |
| 2026-01-12 | Foresite Labs Fund I, L.P. (cluster of 4) | 10%-owner | 411,764 | $6,999,988 | Form 4 |
| 2026-01-12 | Foresite Labs, LLC (cluster of 4) | 10%-owner | 411,764 | $6,999,988 | Form 4 |